Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari Sells 12,000 Shares

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $20.48, for a total value of $245,760.00. Following the completion of the transaction, the chief operating officer now owns 77,363 shares of the company’s stock, valued at $1,584,394.24. The trade was a 13.43 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Eben Tessari also recently made the following trade(s):

• On Monday, February 10th, Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $19.57, for a total transaction of $273,980.00.

Kiniksa Pharmaceuticals Stock Down 3.3 %

KNSA opened at $20.53 on Thursday. The firm has a market cap of $1.49 billion, a price-to-earnings ratio of -146.63 and a beta of 0.31. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $16.56 and a 52 week high of $28.15. The business’s 50 day moving average is $21.03 and its two-hundred day moving average is $21.56.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $122.50 million during the quarter, compared to analysts’ expectations of $123.42 million. During the same quarter last year, the company earned $0.35 EPS. The firm’s revenue for the quarter was up 46.9% compared to the same quarter last year. Equities analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Braidwell LP grew its stake in shares of Kiniksa Pharmaceuticals by 19.3% in the 4th quarter. Braidwell LP now owns 3,452,447 shares of the company’s stock valued at $68,289,000 after purchasing an additional 557,934 shares during the last quarter. Nuveen Asset Management LLC lifted its holdings in shares of Kiniksa Pharmaceuticals by 7.3% during the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company’s stock worth $15,737,000 after purchasing an additional 54,361 shares during the period. Millennium Management LLC grew its position in Kiniksa Pharmaceuticals by 50.9% in the 4th quarter. Millennium Management LLC now owns 779,672 shares of the company’s stock valued at $15,422,000 after buying an additional 263,146 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Kiniksa Pharmaceuticals by 3.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company’s stock valued at $15,262,000 after buying an additional 29,300 shares during the period. Finally, Parkman Healthcare Partners LLC raised its position in Kiniksa Pharmaceuticals by 1.4% during the 4th quarter. Parkman Healthcare Partners LLC now owns 765,453 shares of the company’s stock worth $15,141,000 after buying an additional 10,209 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on KNSA shares. Citigroup assumed coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a “buy” rating and a $40.00 price objective on the stock. Wedbush restated an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Wednesday. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $37.17.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.